Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of using antiretroviral drug resistance testing.

Scandinavian journal of infectious diseases. Supplementum - 1 Jan 2003

Lauria Francesco Nicola, Angeletti Claudio

Abstract excerpt

Human immunodeficiency virus (HIV)-infected patients failing highly active antiretroviral therapy (HAART) have a substantially lower chance of clinical success than naive patients given their first antiretroviral therapy. This suggests that HAART failure is a determinant for an increase in the cost of treatment. A review of the literature regarding cost and impact of antiretroviral drug-resistance testing was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 15000585
DOI: 10.1080/03008870310009687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of using antiretroviral drug resistance testing.PMID 15000585Read ↗

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.Semantic proximity Read ↗

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.Semantic proximity Read ↗

HIV-1 drug resistance genotyping. A review of clinical and economic issues.Semantic proximity Read ↗

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.Semantic proximity Read ↗

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Semantic proximity Read ↗

Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited setting.Semantic proximity Read ↗

The cost of antiretroviral drug resistance in HIV-positive patients.Semantic proximity Read ↗

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income SettingsSemantic proximity Read ↗

[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].Semantic proximity Read ↗

Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysisSemantic proximity Read ↗

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.Semantic proximity Read ↗

A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.